 ROCKVILLE, Md., April 1, 2021 PRNewswire -- Synthetic Biologics, Inc. NYSE American: SYN, a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal GI diseases in areas of high unmet need, today announced that enrollment has commenced and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase IAP. 